
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(5)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

CHECKPOINT THERAPEUTICS, INC.
(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



CHECKPOINT THERAPEUTICS, INC.
2 Gansevoort Street, 9th Floor
New York, NY 10014

**THESE SUPPLEMENTAL PROXY MATERIALS PROVIDE ADDITIONAL INFORMATION REGARDING THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON THURSDAY, JUNE 4, 2020**

On May 22, 2020, Checkpoint Therapeutics, Inc. (the "Company") issued a press release, a copy of which is attached hereto, related to a change to the format of the Company's 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") to be held on Thursday, June 4, 2020. As described below, due to continued public health concerns resulting from the coronavirus ("COVID-19") outbreak, and government-recommended and required limits on public gatherings and to protect the health and safety of the Company's stockholders, directors and employees, the 2020 Annual Meeting will now be held in a virtual-only meeting format.

The Notice of Change to a Virtual Meeting Format, a copy of which is also attached hereto, supplements the 2020 Notice of Annual Meeting of Stockholders and Proxy Statement (the "Proxy Statement") of the Company filed with the Securities and Exchange Commission (the "SEC") on April 24, 2020 and subsequently mailed or made available to the Company's stockholders in connection with the solicitation of proxies by the Company's Board of Directors for use at the 2020 Annual Meeting. The Company's Proxy Statement and 2019 Annual Report are available on the Company's website at www.checkpointtx.com.

These supplemental proxy materials are being filed with the SEC and are being made available to stockholders on or about May 22, 2020. Except as amended or supplemented by the information contained in this supplement, all information set forth in the Proxy Statement continues to apply and should be considered in voting your shares.

THIS NOTICE SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT



Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders

New York, NY – May 22, 2020 – Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (“COVID-19”) outbreak, and government-recommended and required limits on public gatherings. Holding the meeting online will also protect the health and safety of the Company’s stockholders, directors and employees.

The Annual Meeting of Stockholders will begin at 10:00 a.m. Eastern Time on Thursday, June 4, 2020, and will be conducted in a virtual format only. Stockholders will not be able to attend the Annual Meeting in person, however, stockholders of record as of the close of business on April 7, 2020 will be able to vote and view the list of stockholders during the meeting through the online platform.

Investors can access the webcast /conference call and participate in the following ways:

- Visit <http://www.virtualshareholdermeeting.com/CKPT2020> and enter the 16-digit control number included on your Important Notice Regarding the Availability of Proxy Materials, on your proxy card, or on the instructions that accompanied your proxy materials.
- Log into the meeting platform beginning at 9:45 a.m. Eastern Time on June 4, 2020.
- Vote during the Annual Meeting by following the instructions available on the meeting website during the meeting. If you have already voted, no additional action is required.

A list of stockholders entitled to vote at the Annual Meeting will be available for examination for any purpose germane to the Annual Meeting for ten days prior to the Annual Meeting. You may email Checkpoint at ir@checkpointtx.com to coordinate arrangements to view the stockholder list. The stockholder list will also be available during the Annual Meeting at <http://www.virtualshareholdermeeting.com/CKPT2020>.

If you encounter any technical difficulties with the virtual meeting platform on the meeting day, a phone number for technical support will be provided on the meeting page at <http://www.virtualshareholdermeeting.com/CKPT2020>. Technical support will be available beginning at 9:45 a.m. Eastern Time on June 4, 2020 and will remain available until the meeting has ended.

Whether or not stockholders plan to attend the virtual Annual Meeting, Checkpoint urges stockholders to select one of the methods described in the proxy materials to vote and submit their proxies in advance of the meeting.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosbelimab, a potentially differentiated anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including a registration-enabling cohort in cutaneous squamous cell carcinoma intended to support an initial Biologics License Application submission. In addition, Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, a third-generation EGFR inhibitor, in a Phase 1 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.checkpointtx.com.

Company Contacts:

Jaelyn Jaffe and William Begien
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com

Investor Relations Contact:

Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com

Media Relations Contact:

Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com



**NOTICE OF CHANGE OF LOCATION
OF ANNUAL MEETING OF STOCKHOLDERS**

**Thursday, June 4, 2020 at 10:00 a.m. Eastern Time
Virtual Meeting - No Physical Meeting Location**

To the Stockholders of Checkpoint Therapeutics, Inc.:

In light of the coronavirus outbreak ("COVID-19"), public health concerns, and government-recommended and required limits on public gatherings, and to prioritize the health and well-being of our stockholders, directors, employees and other meeting participants, NOTICE IS HEREBY GIVEN that the location of our 2020 Annual Meeting of Stockholders (the "Annual Meeting") has been changed and will be conducted in virtual format only.

The meeting will be held at 10:00 a.m. Eastern Time on June 4, 2020. As described in the proxy materials for the Annual Meeting previously distributed, stockholders of record as of the close of business on April 7, 2020 will be able to vote during the meeting by remote participation.

To participate in the Annual Meeting, visit <http://www.virtualshareholdermeeting.com/CKPT2020> and enter the 16-digit control number included on your Important Notice Regarding the Availability of Proxy Materials, on your proxy card, or on the instructions that accompanied your proxy materials. You may log into the meeting platform beginning at 9:45 a.m. Eastern Time on June 4, 2020. The proxy card included with the proxy materials previously distributed will not be updated to reflect the change in location and may continue to be used to vote your shares in connection with the Annual Meeting. If you have already voted, no additional action is required.

You may vote during the Annual Meeting by following the instructions available on the meeting website during the meeting.

A list of stockholders entitled to vote at the Annual Meeting will be available for examination for any purpose germane to the Annual Meeting for ten days prior to the Annual Meeting. You may email Checkpoint Therapeutics, Inc. at ir@checkpointtx.com to coordinate arrangements to view the stockholder list. The stockholder list will also be available during the Annual Meeting at <http://www.virtualshareholdermeeting.com/CKPT2020>.

If you encounter any technical difficulties with the virtual meeting platform on the meeting day, a phone number for technical support will be provided on the meeting page at <http://www.virtualshareholdermeeting.com/CKPT2020>. Technical support will be available beginning at 9:45 a.m. Eastern Time on June 4, 2020 and will remain available until the meeting has ended.

We thank you for your interest in our company and look forward to your participation at our virtual Annual Meeting.

By Order of the Board of Directors,

A handwritten signature in black ink, appearing to be "GG" followed by a stylized flourish.

Garrett Gray
Corporate Secretary

May 22, 2020
New York, New York
